Nuvation Bio Inc (NUVB)

Jul 28, 2026

Nuvation Bio Inc (NUVB) Valuation: PE, PB & Fair Value Analysis - TradingKey

Jul 28, 2026

Jul 27, 2026

Nuvation Bio Inc (NUVB) Institutional Confidence - TradingKey

Jul 27, 2026

Jul 27, 2026

Nuvation Bio Inc (NUVB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Jul 27, 2026

Jul 27, 2026

Nuvation Bio Inc (NUVB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Jul 27, 2026

Jul 27, 2026

Nuvation Bio Inc (NUVB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Jul 27, 2026

Jul 26, 2026

TradingKey - TradingKey

Jul 26, 2026

Jul 25, 2026

NUVB Stock Is Soaring Today — Why RBC Sees $3B Opportunity In Nuvation Bio's Brain Cancer Drug - Stocktwits

Jul 25, 2026

Jul 25, 2026

Nuvation Bio Inc (NUVB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Jul 25, 2026

Jul 25, 2026

NUVB|Nuvation Bio Inc|Price:6.420|Chg%:-0.055 - TradingKey

Jul 25, 2026

Jul 25, 2026

Nuvation Bio Inc (NUVB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Jul 25, 2026

Jul 24, 2026

Nuvation Bio Inc. (NUVB) Stock Analysis: A Potential 90% Upside In The Biotech Sector - DirectorsTalk Interviews

Jul 24, 2026

Jul 24, 2026

Nuvation Bio Inc (NUVB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Jul 24, 2026

Jul 23, 2026

Nuvation Bio to report Q2 2026 results on August 6 - scanx.trade

Jul 23, 2026

Jul 22, 2026

RBC Capital reiterates Nuvation Bio stock rating on pipeline potential - Investing.com India

Jul 22, 2026

Jul 22, 2026

Nuvation Bio To Report Second Quarter 2026 Financial Results - TradingView

Jul 22, 2026

Jul 22, 2026

Nuvation Bio to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026 - Yahoo Finance

Jul 22, 2026

Jul 22, 2026

Nuvation Bio's Safusidenib Clinical Program, Ibtrozi Opportunity Create Favorable Setup, RBC Says - Moomoo

Jul 22, 2026

Jul 22, 2026

RBC Capital reiterates Nuvation Bio stock rating on pipeline potential By Investing.com - Investing.com South Africa

Jul 22, 2026

Jul 22, 2026

Truist Financial Maintains Nuvation Bio(NUVB.US) With Buy Rating - Moomoo

Jul 22, 2026

Jul 22, 2026

Nuvation Bio (NUVB) Could Be 48% Undervalued As Safusidenib Data Strengthens Its Case - Sahm

Jul 22, 2026

Jul 22, 2026

Frontier tech research, news & data - MLQ.ai

Jul 22, 2026

Jul 21, 2026

JonesTrading Maintains Nuvation Bio(NUVB.US) With Buy Rating, Maintains Target Price $12 - Moomoo

Jul 21, 2026

Jul 21, 2026

Nuvation Bio (NUVB) Soars 7.9%: Is Further Upside Left in the Stock? - Yahoo Finance

Jul 21, 2026

Jul 21, 2026

Developing Better Drugs, Not Just More Drugs: Q&A with David Hung - Pharmaceutical Executive

Jul 21, 2026

Jul 20, 2026

symbol__ Stock Quote Price and Forecast - CNN

Jul 20, 2026

Jul 20, 2026

Nuvation Bio stock jumps on safusidenib trial expansion plans - Investing.com India

Jul 20, 2026

Jul 20, 2026

Nuvation Bio stock jumps on safusidenib trial expansion plans By Investing.com - Investing.com Nigeria

Jul 20, 2026

Jul 20, 2026

RBC Capital Maintains Nuvation Bio(NUVB.US) With Buy Rating, Maintains Target Price $19 - Moomoo

Jul 20, 2026

Jul 20, 2026

BUZZ-U.S. STOCKS ON THE MOVE-Yum Brands, AMD, Nuvation Bio - Bitget

Jul 20, 2026

Jul 20, 2026

NUVB Stock Slides On Financing As Bullish Analysts Double Down - StocksToTrade

Jul 20, 2026

Jul 20, 2026

Nuvation Bio to advance glioma drug to Phase III trial after positive three-year data - Yahoo

Jul 20, 2026

Jul 20, 2026

Nuvation Bio reports 51.9% response rate for safusidenib in Phase 2 glioma study - grafa.com

Jul 20, 2026

Jul 20, 2026

Why Is Nuvation Bio Stock Gaining Monday? - Benzinga

Jul 20, 2026

Jul 20, 2026

Nuvation Bio posts corporate deck highlighting IBTROZI ROS1+ NSCLC launch, safusidenib IDH1 glioma program - Bitget

Jul 20, 2026

Jul 20, 2026

Nuvation Bio (NUVB) Corporate presentation Summary - Quartr

Jul 20, 2026

Jul 20, 2026

Nuvation Bio expands safusidenib program with two new studies By Investing.com - Investing.com Nigeria

Jul 20, 2026

Jul 20, 2026

Nuvation Bio expands safusidenib program with two new studies - Investing.com

Jul 20, 2026

Jul 20, 2026

Nuvation Bio Announces Positive Updated Phase 2 Data and Expansion of Safusidenib Clinical Program with Two New Studies to Explore Broad Spectrum of IDH1-Mutant Glioma - Investing News Network

Jul 20, 2026

Jul 20, 2026

NUVB: IBTROZI's global success and a robust pipeline drive growth in high-value oncology markets - TradingView

Jul 20, 2026

Jul 17, 2026

Form 4 Nuvation Bio Inc For: 17 July By Investing.com - Investing.com South Africa

Jul 17, 2026

Jul 17, 2026

Nuvation Bio (NUVB) CFO exercises 40,000 share options and boosts holdings - Stock Titan

Jul 17, 2026

Jul 17, 2026

Nuvation Bio Inc. (NUVB) Investigation: Bronstein, Gewirtz & Gros - The National Law Review

Jul 17, 2026

Jul 17, 2026

How Nuvation Bio Manages its Ongoing Clinical Trials - Pharmaceutical Executive

Jul 17, 2026

Jul 16, 2026

Goodwin Advises On Nuvation Bio’s $287.5 Million Registered Convertible Senior Notes Offering With Capped Call - Mondaq

Jul 16, 2026

Jul 16, 2026

The Status of Nuvation Bio’s Pipeline - Pharmaceutical Executive

Jul 16, 2026

Jul 15, 2026

Nuvation Bio’s Global Strategy - Pharmaceutical Executive

Jul 15, 2026

Jul 15, 2026

RBC Capital Cuts PT on Nuvation Bio (NUVB) in Q2 Preview - Yahoo Finance

Jul 15, 2026